Zdrowie i gospodarka · 03/07/2019

FDA Clears CLAFORAN (Cefotaxime Sodium) for Injection for Continued Sale

The US Food and Drug Administration (FDA) has ruled that CLAFORAN (cefotaxime sodium) for injection in various strengths was not withdrawn from the market due to safety or efficacy concerns, allowing the agency to continue approving abbreviated new drug applications (ANDAs) for the product.